Low-dose risperidone augmentation of fluvoxamine treatment in obsessive-compulsive disorder: a double-blind, placebo-controlled study.
about
Atypical antipsychotic augmentation in SSRI treatment refractory obsessive-compulsive disorder: a systematic review and meta-analysisCurrent trends in drug treatment of obsessive–compulsive disorderSecond-generation antipsychotics for obsessive compulsive disorderPharmacotherapy augmentation strategies in treatment-resistant anxiety disordersPharmacotherapy of obsessive-compulsive disorder during pregnancy: a clinical approachCanadian clinical practice guidelines for the management of anxiety, posttraumatic stress and obsessive-compulsive disordersA comparison of low-dose risperidone to paroxetine in the treatment of panic attacks: a randomized, single-blind study.A systematic review: antipsychotic augmentation with treatment refractory obsessive-compulsive disorder.A psychopharmacological treatment algorithm for generalised anxiety disorder (GAD)Antipsychotic augmentation of serotonin reuptake inhibitors in treatment-resistant obsessive-compulsive disorder: a meta-analysis of double-blind, randomized, placebo-controlled trials.Clinical treatment of obsessive compulsive disorderEvidence-based guidelines for the pharmacological treatment of anxiety disorders: recommendations from the British Association for Psychopharmacology.Pharmacotherapies in the management of obsessive-compulsive disorder.World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the pharmacological treatment of anxiety, obsessive-compulsive and post-traumatic stress disorders - first revision.Psychotherapy and medication management strategies for obsessive-compulsive disorder.Assessment and management of treatment-refractory obsessive-compulsive disorder in children.Six-month outcomes from a randomized trial augmenting serotonin reuptake inhibitors with exposure and response prevention or risperidone in adults with obsessive-compulsive disorder.Augmenting serotonin reuptake inhibitors in obsessive-compulsive disorder: What moderates improvement?Antipsychotic Augmentation of Serotonin Reuptake Inhibitors in Treatment-Resistant Obsessive-Compulsive Disorder: An Update Meta-Analysis of Double-Blind, Randomized, Placebo-Controlled Trials.A review of antipsychotics in the treatment of obsessive compulsive disorder.Fluvoxamine: a selective serotonin re-uptake inhibitor for the treatment of obsessive-compulsive disorder.An update on the pharmacological treatment of obsessive-compulsive disorder.Novel uses for risperidone: focus on depressive, anxiety and behavioral disorders.Should psychiatrists use atypical antipsychotics to treat nonpsychotic anxiety?Euprolactinemic gynecomastia and galactorrhea with risperidone-fluvoxamine combination.Exposure and response prevention helps adults with obsessive-compulsive disorder who do not respond to pharmacological augmentation strategies.Cognitive-behavioral therapy vs risperidone for augmenting serotonin reuptake inhibitors in obsessive-compulsive disorder: a randomized clinical trial.Emerging drugs for panic disorder.Augmentation strategies in obsessive-compulsive disorder.The potential role of atypical antipsychotics in the treatment of panic disorder.Obsessive-compulsive disorder: Insights from animal models.Responsiveness of 5-HT(1A) and 5-HT2 receptors in the rat orbitofrontal cortex after long-term serotonin reuptake inhibition.Atypical antipsychotics for mood and anxiety disorders: safe and effective adjuncts?Augmentation with cognitive behavioural therapy has superior efficacy to augmentation with risperidone for treating adults with treatment-resistant OCD.Peromyscus maniculatus bairdii as a naturalistic mammalian model of obsessive-compulsive disorder: current status and future challenges.Successful treatment for obsessive-compulsive disorder with addition of low-dose risperidone to fluvoxamine: implications for plasma levels of catecholamine metabolites and serum brain-derived neurotrophic factor levels.Activation of serotonin 5-HT2A receptors inhibits high compulsive drinking on schedule-induced polydipsia.D2 and D3 dopamine receptor affinity predicts effectiveness of antipsychotic drugs in obsessive-compulsive disorders: a metaregression analysisCritical Review of the Use of Second-Generation Antipsychotics in Obsessive-Compulsive and Related Disorders
P2860
Q21999508-2098CC52-B223-480E-A692-758263DC599FQ22305853-9F1E753A-94FE-4EC5-8FAA-CD8B65F39BA4Q24235770-DD1D6238-B409-4DCD-A007-EC760C583798Q24243827-7E1DD07D-C4FE-43F6-9E59-7E89B3D6EE8BQ26774013-ECFFA564-1C92-43EA-9B8F-7B6DF8002E96Q27009995-812EDE9F-BB88-4FC2-B55A-D3A0506897EEQ33452892-12CD7253-04BC-4CF9-A722-6DE0F7DD7B5EQ33994634-9AB9E3CB-DBA5-45F5-8364-AF8C2E46082BQ34183517-ED6AC3BD-63EF-4AAC-8C6D-1D8D9E1D7BEBQ34296626-0A015F1F-FE07-4E6F-84E5-C9E89199551CQ34359796-9FB4E095-3FDE-4AF6-8528-D36BF5862F67Q34465555-AC9CE9B4-4167-4DF7-9CE9-0F33FD59A76FQ34547177-CCBDD4E7-EFDC-4611-B009-6DF6550F6F63Q34865036-C789A17A-3F21-4CBA-8321-97F6189C3D08Q35212987-EB8991DB-1710-4C56-B6F5-4FD8C88C4182Q35697831-E653314B-21CD-42F6-AA37-2E8BF81AD906Q35914688-72803C86-0E81-4810-BA5B-651565CBB363Q36068947-E4A854D2-A022-4835-AFCA-B75353354E5BQ36077216-BF0E00C0-CF43-4395-AEA0-55978383287CQ36276544-093E2B20-18EA-4E5D-9BB7-535EE12C8851Q36326268-7BCA21E8-7E6B-4DB5-8AE4-B508F593DE28Q36765772-B3B458CE-80D2-4004-A489-B44B5A15C5DCQ36904901-A2384E71-3931-4709-9B2B-305C4FE0D22AQ37289300-A300D71F-D385-4B13-AC38-2CBFE70431BCQ37300013-E2CF4C6A-9D36-46B3-A4F3-A815E6168512Q37468737-1D58E8BB-2D83-43DD-B4E2-3007C910A252Q37639264-AA252815-2A99-43FD-884D-19C806E70D56Q37945699-B31A1017-1C81-4CC6-AD77-A564FDD8B486Q38078029-2328ABE2-865F-4E48-A8A8-8861B8B7C067Q38246661-95EF2E19-7BDE-4837-84AA-9F019A947489Q38832138-2D0F8992-A695-471C-86ED-8021FAA2C3E3Q41971125-7B1005E7-010E-4B76-BEF9-AE970152ED20Q42878138-A52BFE09-8CEF-42EF-9F34-CFD67EF61385Q46133444-2F3430AB-8AEE-4272-83EF-2ACBFA2744DAQ47566821-4D48CA0D-61B0-4083-8DC4-88741AB09119Q48518653-366DC643-3389-410B-B57B-D6FC2EFFEC16Q48586285-B9ADA3A9-D1EA-4C1A-A15F-AF28920721ABQ57700334-17EB0B45-F97D-4C22-BC50-E81074189DF9Q58780376-14FA0D48-9DF1-4C2D-9DFB-425407BA1402
P2860
Low-dose risperidone augmentation of fluvoxamine treatment in obsessive-compulsive disorder: a double-blind, placebo-controlled study.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
2005年论文
@zh
2005年论文
@zh-cn
name
Low-dose risperidone augmentat ...... ind, placebo-controlled study.
@en
Low-dose risperidone augmentat ...... ind, placebo-controlled study.
@nl
type
label
Low-dose risperidone augmentat ...... ind, placebo-controlled study.
@en
Low-dose risperidone augmentat ...... ind, placebo-controlled study.
@nl
prefLabel
Low-dose risperidone augmentat ...... ind, placebo-controlled study.
@en
Low-dose risperidone augmentat ...... ind, placebo-controlled study.
@nl
P2093
P1476
Low-dose risperidone augmentat ...... ind, placebo-controlled study.
@en
P2093
Emanuela Guglielmo
Francesca Siliprandi
Laura Bellodi
Stefano Erzegovesi
P356
10.1016/J.EURONEURO.2004.04.004
P407
P577
2005-01-01T00:00:00Z